Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Solasia Pharma KK's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasia Pharma KK Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Solasia Pharma KK's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solasia Pharma KK (FRA:9SO) has a Buyback Yield % of -12.86 as of Jul. 15, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Solasia Pharma KK and its competitors. According to the industry distribution chart, Solasia Pharma KK ranks #234 out of 290 companies in the Drug Manufacturers industry, placing it in the top 80.7%.
Is Solasia Pharma KK's Buyback Yield % too high?
Solasia Pharma KK's current Buyback Yield % is -12.86. Based on the distribution chart, Solasia Pharma KK ranks #234 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Solasia Pharma KK has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Solasia Pharma KK ranks #234 out of 290 companies for Buyback Yield %. This places Solasia Pharma KK in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Solasia Pharma KK and its competitors. Solasia Pharma KK's current Buyback Yield % is -12.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (FRA:9SO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.13 — trading 1170% above its estimated fair value. The current Buyback Yield % is -12.86. Solasia Pharma KK's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Solasia Pharma KK (FRA:9SO), the current Buyback Yield % is -12.86 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasia Pharma KK (FRA:9SO) Overvalued in 2026?
Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be overvalued.
The current stock price of €0.13 is trading 1170% above its estimated GF Value™ of €0.01.
GuruFocus considers Solasia Pharma KK to be Significantly Overvalued.
Key valuation signals for FRA:9SO:
Buyback Yield %: -12.86
GF Value™: €0.01 vs. price of €0.13 (1170% above fair value)
No single metric tells the full story. See the FRA:9SO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9SO has been successfully added to your 
